The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., Mar. 30, 4:02 PM

Slide #23. Concert Pharmaceuticals, Inc. Secondary Offering

Company: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)
Date announced: 3/18/2015
Shares Offered: 3,300,000
Date of Pricing: 3/19/2015
Price Per Share: $15.15
Secondary Offering Details: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it has commenced an underwritten public offering of its common stock. All of the shares in the offering are to be sold by Concert. - updated 3/19 - Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the pricing of an underwritten public offering of 3,300,000 shares of its common stock at a public offering price of $15.15 per share. In addition, Concert has granted the underwriters a 30-day option to purchase up to an additional 495,000 shares of common stock.

Concert Pharmaceuticals is a clinical stage biopharmaceutical company engaged in developing small molecule drugs. Co.'s pipeline includes three clinical-stage candidates and a number of preclinical compounds that it is developing. Co.'s clinical programs are CTP-354 for spasticity associated with multiple sclerosis and spinal cord injury, CTP-499 for diabetic kidney disease and AVP-786 for neurologic and psychiatric disorders under its collaboration with Avanir Pharmaceuticals, Inc. Co. also has ongoing collaborations with Celgene International Sarl, for deuterated compounds including CTP-730 for inflammatory diseases, and Jazz Pharmaceuticals Ireland Limited, for JZP-386 for narcolepsy.
Open the CNCE Page at The Online Investor »

Company Name:  Concert Pharmaceuticals Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding CNCE:  3
Total Market Value Held by ETFs:  $3.66M
Total Market Capitalization:  $247.00M
% of Market Cap. Held by ETFs:  1.48%

Open the CNCE Page at The Online Investor (in a new window) »

March 30, 2015    4:02 PM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
93rd percentile
(ranked higher than approx. 93% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.